PMID- 28110421
OWN - NLM
STAT- MEDLINE
DCOM- 20171009
LR  - 20181113
IS  - 1548-3576 (Electronic)
IS  - 1548-3568 (Print)
IS  - 1548-3568 (Linking)
VI  - 14
IP  - 1
DP  - 2017 Feb
TI  - Dendritic Cell Immune Responses in HIV-1 Controllers.
PG  - 1-7
LID - 10.1007/s11904-017-0345-0 [doi]
AB  - PURPOSE OF REVIEW: Robust HIV-1-specific CD8 T cell responses are currently 
      regarded as the main correlate of immune defense in rare individuals who achieve 
      natural, drug-free control of HIV-1; however, the mechanisms that support 
      evolution of such powerful immune responses are not well understood. Dendritic 
      cells (DCs) are specialized innate immune cells critical for immune recognition, 
      immune regulation, and immune induction, but their possible contribution to HIV-1 
      immune defense in controllers remains ill-defined. RECENT FINDINGS: Recent 
      studies suggest that myeloid DCs from controllers have improved abilities to 
      recognize HIV-1 through cytoplasmic immune sensors, resulting in more potent, 
      cell-intrinsic type I interferon secretion in response to viral infection. This 
      innate immune response may facilitate DC-mediated induction of highly potent 
      antiviral HIV-1-specific T cells. Moreover, protective HLA class I isotypes 
      restricting HIV-1-specific CD8 T cells may influence DC function through specific 
      interactions with innate myelomonocytic MHC class I receptors from the leukocyte 
      immunoglobulin-like receptor family. Bi-directional interactions between 
      dendritic cells and HIV-1-specific T cells may contribute to natural HIV-1 immune 
      control, highlighting the importance of a fine-tuned interplay between innate and 
      adaptive immune activities for effective antiviral immune defense.
FAU - Martin-Gayo, Enrique
AU  - Martin-Gayo E
AD  - Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, 400 
      Technology Square, Cambridge, MA, 02139, USA.
FAU - Yu, Xu G
AU  - Yu XG
AD  - Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, 400 
      Technology Square, Cambridge, MA, 02139, USA. xyu@mgh.harvard.edu.
LA  - eng
GR  - R01 AI078799/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr HIV/AIDS Rep
JT  - Current HIV/AIDS reports
JID - 101235661
SB  - IM
MH  - Dendritic Cells/*immunology
MH  - HIV Infections/*immunology
MH  - *HIV-1
MH  - Humans
PMC - PMC5552363
MID - NIHMS885082
OTO - NOTNLM
OT  - CD8 T cells
OT  - Dendritic cell immune responses
OT  - Dendritic cells
OT  - HIV-1 controllers
OT  - HIV-1 immune defense
COIS- Compliance with Ethical Standards: Conflict of Interest: Enrique Martin-Gayo and 
      Xu G. Yu declare that they have no conflict of interest.
EDAT- 2017/01/23 06:00
MHDA- 2017/10/11 06:00
PMCR- 2017/08/10
CRDT- 2017/01/23 06:00
PHST- 2017/01/23 06:00 [pubmed]
PHST- 2017/10/11 06:00 [medline]
PHST- 2017/01/23 06:00 [entrez]
PHST- 2017/08/10 00:00 [pmc-release]
AID - 10.1007/s11904-017-0345-0 [pii]
AID - 10.1007/s11904-017-0345-0 [doi]
PST - ppublish
SO  - Curr HIV/AIDS Rep. 2017 Feb;14(1):1-7. doi: 10.1007/s11904-017-0345-0.